Dynorphin‐based “release on demand” gene therapy for drug‐resistant temporal lobe epilepsy
Dynorphin‐based “release on demand” gene therapy for drug‐resistant temporal lobe epilepsy
About this item
Full title
Author / Creator
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
Focal epilepsy represents one of the most common chronic CNS diseases. The high incidence of drug resistance, devastating comorbidities, and insufficient responsiveness to surgery pose unmet medical challenges. In the quest of novel, disease‐modifying treatment strategies of neuropeptides represent promising candidates. Here, we provide the “proof...
Alternative Titles
Full title
Dynorphin‐based “release on demand” gene therapy for drug‐resistant temporal lobe epilepsy
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_480489b3db774418b348f8ecb6933d15
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_480489b3db774418b348f8ecb6933d15
Other Identifiers
ISSN
1757-4676,1757-4684
E-ISSN
1757-4684
DOI
10.15252/emmm.201809963
